第一章 概述/ 1
1 中国人群肿瘤登记系统 / 1
2 本年报数据 / 3
2. 1 数据上报地区及范围 / 3
2. 2 数据质量控制及最终纳入数据 / 3
2. 3 年报内容 / 4
第二章 方法和指标/ 5
1 建立肿瘤登记处 / 5
2 资料收集方法 / 7
2. 1 信息收集渠道 / 8
2. 2 病例核实工作 / 8
2. 3 随访工作 / 8
3 数据收集/ 10
3. 1 新发病例数据/ 10
3. 2 死亡数据/ 10
3. 3 生存随访数据/ 10
3. 4 人口数据/ 10
4 质量控制/ 11
4. 1 可比性/ 11
4. 2 完整性/ 11
4. 3 有效性/ 11
4. 4 时效性/ 12
5 资料质量控制流程/ 12
6 统计分类/ 14
6. 1 癌症分类/ 14
6. 2 自然地区分类/ 17
7 常用统计指标/ 18
7. 1 年平均人口数/ 18
7. 2 性别、年龄别人口数 / 18
7. 3 发病(死亡)率 / 18
7. 4 年龄别发病(死亡)率 / 18
7. 5 年龄调整率(标准化率) / 19
7. 6 分类构成/ 20
7. 7 累积发病(死亡)率 / 20
7. 8 截缩发病(死亡)率 / 20
8 生存率/ 21
8. 1 观察生存率/ 21
8. 2 调整生存率/净生存率 / 21
8. 3 相对生存率/ 22
2020 中国肿瘤登记年报 9
Chapter 1 Introduction / 1
1 Population-based cancer registration system in China / 1
2 Data specification in this annual report / 3
2. 1 Data collection scope / 3
2. 2 Data quality control and qualified data / 3
2. 3 Content of this annual report / 4
Chapter 2 Method and index / 5
1 Establishing a cancer registry / 5
2 Methods of data collection / 7
2. 1 Data collecting channels / 8
2. 2 Cancer case certification / 8
2. 3 Follow-up practice / 8
3 Data collection / 10
3. 1 Incidence data / 10
3. 2 Mortality data / 10
3. 3 Survival data / 10
3. 4 Population data / 10
4 Quality control / 11
4. 1 Comparability / 11
4. 2 Completeness / 11
4. 3 Validity / 11
4. 4 Timeliness / 12
5 Flow diagram of data quality control / 12
6 Classification and coding / 14
6. 1 Cancer classification / 14
6. 2 Area classification / 17
7 Statistical indicators / 18
7. 1 Average annual population / 18
7. 2 Sex- and age-specific population / 18
7. 3 Incidence (mortality) rate / 18
7. 4 Age-specific incidence (mortality) rate / 18
7. 5 Age-standardized rate (ASR) / 19
7. 6 Relative frequency / 20
7. 7 Cumulative incidence (mortality) rate / 20
7. 8 Truncated incidence (mortality) rate / 20
8 Survival rate / 21
8. 1 Observed survival rate / 21
8. 2 Adjusted survival/ net survival rate / 21
8. 3 Relative survival rate / 22
10 CHINA CANCER REGISTRY ANNUAL REPORT 2020
第三章 数据质量评价 / 23
1 数据来源/ 23
2 数据纳入标准/ 31
3 肿瘤登记资料评价/ 32
3. 1 覆盖人口、发病数和死亡数 / 32
3. 2 数据质量评价/ 32
4 本年报收录登记地区的选取与数据质量评价/ 64
4. 1 年报收录登记地区的选取/ 64
4. 2 全国登记地区数据质量评价指标/ 64
第四章 2017 年中国肿瘤登记地区癌症发病与死亡/ 66
1 中国肿瘤登记地区覆盖人口/ 66
2 中国肿瘤登记地区全部癌症发病与死亡/ 70
2. 1 中国肿瘤登记地区全部癌症发病情况/ 70
2. 2 中国肿瘤登记地区全部癌症年龄别发病率/ 71
2. 3 中国肿瘤登记地区全部癌症死亡情况/ 75
2. 4 中国肿瘤登记地区全部癌症年龄别死亡率/ 76
2. 5 中国不同肿瘤登记地区全部癌症发病和死亡情况/ 80
3 中国肿瘤登记地区前10 位癌症发病与死亡 / 82
3. 1 中国肿瘤登记地区前10 位癌症发病情况 / 82
3. 2 中国肿瘤登记地区前10 位癌症死亡情况 / 84
3. 3 中国城市肿瘤登记地区前10 位癌症发病情况 / 86
3. 4 中国城市肿瘤登记地区前10 位癌症死亡情况 / 88
3. 5 中国农村肿瘤登记地区前10 位癌症发病情况 / 90
3. 6 中国农村肿瘤登记地区前10 位癌症死亡情况 / 92
3. 7 中国东部肿瘤登记地区前10 位癌症发病情况 / 94
3. 8 中国东部肿瘤登记地区前10 位癌症死亡情况 / 96
3. 9 中国中部肿瘤登记地区前10 位癌症发病情况 / 98
3. 10 中国中部肿瘤登记地区前10 位癌症死亡情况 / 100
3. 11 中国西部肿瘤登记地区前10 位癌症发病情况 / 102
3. 12 中国西部肿瘤登记地区前10 位癌症死亡情况 / 104
第五章 各部位癌症的发病与死亡/ 106
1 口腔和咽(除外鼻咽) / 106
2 鼻咽 / 112
3 食管 / 116
4 胃 / 122
5 结直肠 / 128
6 肝 / 136
7 胆囊 / 140
8 胰腺 / 144
9 喉 / 149
10 肺/ 153
11 骨/ 159
12 女性乳腺/ 164
2020 中国肿瘤登记年报 11
Chapter 3 Evaluation of data quality / 23
1 Data sources / 23
2 Data inclusion criteria / 31
3 Evaluation of cancer registration data / 32
3. 1 Population coverage, new cancer cases and cancer deaths / 32
3. 2 Evaluation of data quality / 32
4 Coverage and data quality of cancer registries in this annual report / 64
4. 1 Coverage of cancer registries in this annual report / 64
4. 2 Evaluation of data quality / 64
Chapter 4 Cancer incidence and mortality in the registration areas of China, 2017 / 66
1 Population coverage in cancer registration areas of China / 66
2 Incidence and mortality for all cancer sites in the registration areas of China / 70
2. 1 Incidence for all cancer sites in the registration areas of China / 70
2. 2 Age-specific incidence rates for all cancer sites in the registration areas of China / 71
2. 3 Mortality for all cancer sites in the registration areas of China / 75
2. 4 Age-specific mortality rates for all cancer sites in the registration areas of China / 76
2. 5 Incidence and mortality for all cancer sites in different registration areas of China / 80
3 Top ten leading causes of new cancer cases and deaths in the registration areas of China / 82
3. 1 Top ten leading causes of new cancer cases in the registration areas of China / 82
3. 2 Top ten leading causes of cancer deaths in the registration areas of China / 84
3. 3 Top ten leading causes of new cancer cases in urban registration areas of China / 86
3. 4 Top ten leading causes of cancer deaths in urban registration areas of China / 88
3. 5 Top ten leading causes of new cancer cases in rural registration areas of China / 90
3. 6 Top ten leading causes of cancer deaths in rural registration areas of China / 92
3. 7 Top ten leading causes of new cancer cases in eastern registration areas of China / 94
3. 8 Top ten leading causes of cancer deaths in eastern registration areas of China / 96
3. 9 Top ten leading causes of new cancer cases in central registration areas of China / 98
3. 10 Top ten leading causes of cancer deaths in central registration areas of China / 100
3. 11 Top ten leading causes of new cancer cases in western registration areas of China / 102
3. 12 Top ten leading causes of cancer deaths in western registration areas of China / 104
Chapter 5 Cancer incidence and mortality by site / 106
1 Oral cavity & pharynx(except nasopharynx) / 106
2 Nasopharynx / 112
3 Esophagus / 116
4 Stomach / 122
5 Colon-rectum / 128
6 Liver / 136
7 Gallbladder / 140
8 Pancreas / 144
9 Larynx / 149
10 Lung / 153
11 Bone / 159
12 Female breast / 164
12 CHINA CANCER REGISTRY ANNUAL REPORT 2020
13 子宫颈/ 170
14 子宫体/ 175
15 卵巢/ 179
16 前列腺/ 183
17 肾及泌尿系统不明/ 187
18 膀胱/ 196
19 脑/ 202
20 甲状腺/ 208
21 淋巴瘤/ 214
22 白血病/ 220
附录/ 228
附录1 2017 年全国肿瘤登记地区癌症发病和死亡结果 / 228
附录2 2017 年全国东中西部肿瘤登记地区癌症发病和死亡结果/ 264
鸣谢/ 282
13 Cervix / 170
14 Uterus / 175
15 Ovary / 179
16 Prostate / 183
17 Kidney & unspecified urinary organs / 187
18 Bladder / 196
19 Brain / 202
20 Thyroid / 208
21 Lymphoma / 214
22 Leukemia / 220
Appendix / 229
Appendix 1 Cancer incidence and mortality in registration areas of China 2017 / 229
Appendix 2 Cancer incidence and mortality in Eastern Central and Western registration areas
of China 2017 / 264Acknowledgement / 282